| ¿µ¹® | population | ÇÑ±Û | ¸ðÁý´Ü |
|---|---|---|---|
| ¼³¸í | Åë°è¿ë¾î·Î, Åë°èÀûÀÎ °üÂûÀÇ ´ë»óÀÌ µÇ´Â Áý´Ü Àüü. ÃøÁ¤À̳ª Á¶»ç¸¦ Çϱâ À§ÇÏ¿© Ç¥º»À» »Ì¾Æ³»´Â ¹ÙÅÁÀÌ µÈ´Ù. ÀÌ¿¡ ´ëÇØ ¸ðÁý´Ü¿¡¼ ¼±ÃâµÈ ÀϺδ ǥº»À̶ó°í ÇÑ´Ù. ½ÇÁ¦ Á¶»ç¿¡¼´Â ¸ðÁý´ÜÀÇ ¸ðµç Á¤º¸¸¦ ÆÄ¾ÇÇÏ´Â °ÍÀÌ °ï¶õÇϱ⠶§¹®¿¡, ÃßÃâÇÑ Ç¥º»¿¡ ±âÃÊÇÏ¿© ¸ðÁý´Ü¿¡ ´ëÇØ¼ °á·ÐÀ» ³»¸®°Ô µÈ´Ù. |
||
| ¿µ¹® | upper GI series | ÇÑ±Û | »óºÎÀ§Àå°üÁ¶¿µ¼ú |
|---|---|---|---|
| ¼³¸í | X-¼± »çÁø¿¡¼ Àß ³ªÅ¸³ª´Â Á¶¿µÁ¦(¹æ»ç¼±ÃÔ¿µ»ó¿¡¼ ÇϾé°Ô ³ªÅ¸³ª ÁÖÀ§Á¶Á÷°ú °¨º°ÀÌ ¿ëÀÌÇÏ´Ù)¸¦ ¼·ÃëÇÑ ÈÄ ½Äµµ, À§, »ùâÀÚ, ÀÛÀºÃ¢ÀÚ»óºÎ±îÁö X-¼± ÃÔ¿µÇϹǷνá, ±×°÷ ¼ÒȰü³»ÀÇ ÀÌ»óº´ÅÍ¿©ºÎ¸¦ °Ë»çÇÏ´Â °Í. Á¶¿µÁ¦´Â ÁÖ·Î ¹Ù·ýÀ» »ç¿ëÇÏ¸ç ´õ ¼±¸íÇÑ ¿µ»óÀ» ¾ò±âÀ§ÇØ ¹ßÆ÷Á¦¸¦ ÇÔ²² ¼·ÃëÇÏ¿© ¹Ù·ý°ú °ø±âÀÇ ÀÌÁßÁ¶¿µÃÔ¿µÀ» Çϱ⵵ ÇÑ´Ù. ½Äµµ¾Ï, À§¾Ï ¹× ¼Òȼº±Ë¾ç°ú ±×¹Û¿¡ ´Ù¾çÇÑ º´º¯ÀÇ Áø´Ü¿¡ È¿°úÀûÀ¸·Î »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | population | ÇÑ±Û | Àα¸, ¸ðÁý´Ü |
|---|---|---|---|
| ¼³¸í | ¼ö ¼¼´ë¸¦ ÅëÇÏ¿© À¯Àü¼º ¹× ¹®ÈÀû °è¼Ó¼º¿¡ ÀÇÇÏ¿© Ư¡Áö¿öÁö°í, ÀÎÁ¢ÇÏ¿© ºÐÆ÷Çϰí ÀÖ´Â ÀÏÁ¤ÇÑ Áö¿ª¿¡ »ç´Â »ç¶÷ÀÇ ¼ö. |
||
| ¿µ¹® | small bowel series | ÇÑ±Û | ÀÛÀºÃ¢ÀÚ Á¶¿µ¼ú, ¼ÒÀå Á¶¿µ¼ú |
|---|---|---|---|
| ¼³¸í | ¹æ»ç¼± Á¶¿µÁ¦(¹æ»ç¼±°Ë»ç¿¡¼ ´Ù¸¥ ºÎÀ§¿Í ´ëÁ¶µÇ´Â ¾ÆÁÖ Èò»öÀ» ¶ì´Â ¹°Áú)ÀÎ ¹Ù·ýÀ» ¼·ÃëÇÑ µÚ, ÃÔ¿µÇÏ´Â ÀÛÀºÃ¢ÀÚÀÇ ±âº»ÀûÀÎ ¹æ»ç¼± °Ë»ç·Î¼, ¹æ¹ýÀº 200~300mLÀÇ ¹Ù·ýÀ» ¸ÔÀºµÚ ¹Ù·ýÀÌ ÀÛÀº âÀÚ¸¦ Åë°úÇÏ´Â µ¿¾È Á¤±ÔÀû °£°ÝÀ¸·Î ¹æ»ç¼± »çÁøÀ» ÂïÀ½. ÀϹÝÀûÀ¸·Î 2~3½Ã°£ÀÌ °É¸². |
||
| PGA1-3 | prostaglandins A1 to A3 |
|---|---|
| PGE, PGE1, | PGE2 prostaglandins E, E1, E2 |
| PGF, PGF1, | PGF2 prostaglandins F, F1, F2 |
| UGIS | Upper Gastro-Intestinal Series |
| FMS | fat-mobilizing substance; Fellow of the Medical Society; fibromyalgia syndrome; full mouth series |
| SEC | Series elastic component |
|---|---|
| PGE1 | Prostaglandins E1 |
| PGF2 alpha | Prostaglandins F2 alpha |
| PGE2 | Prostaglandins E1 and E2 |
| CPS | Current Population Survey |
seriflux
| annual reports | Annual statements concerning the administrative and operational functions of an institution or organization. (12 Dec 1998) |
|---|---|
| prostaglandins | A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. (12 Dec 1998) |
| prostaglandins a | (13e,15s)-15-hydroxy-9-oxoprosta-10,13-dien-1-oic acid (pga(1)); (5z,13e,15s)-15-hydroxy-9-oxoprosta-5,10,13-trien-1-oic acid (pga(2)); (5z,13e,15s,17z)-15-hydroxy-9-oxoprosta-5,10,13,17-tetraen-1-oic acid (pga(3)). A group of naturally occurring secondary prostaglandins derived from pge. Pga(1) and pga(2) as well as their 19-hydroxy derivatives are found in many organs and tissues. (12 Dec 1998) |
| prostaglandins a, synthetic | Analogs or derivatives of prostaglandin a that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pga. (12 Dec 1998) |
| prostaglandins b | Physiologically active prostaglandins found in many tissues and organs. They are potent pressor substances and have many other physiological activities. (12 Dec 1998) |
| prostaglandins d | Physiologically active prostaglandins found in many tissues and organs. They show pressor activity, are mediators of inflammation, and have potential antithrombotic effects. (12 Dec 1998) |
| prostaglandins e | (11 alpha,13e,15s)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (pge(1)); (5z,11 alpha,13e,15s)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (pge(2)); and (5z,11 alpha,13e,15s,17z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (pge(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. (12 Dec 1998) |
| prostaglandins e, synthetic | Analogs or derivatives of prostaglandins e that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pge. (12 Dec 1998) |
| prostaglandins f | (9 alpha,11 alpha,13e,15s)-9,11,15-trihydroxyprost-13-en-1-oic acid (pgf(1 alpha)); (5z,9 alpha,11,alpha,13e,15s)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (pgf(2 alpha)); (5z,9 alpha,11 alpha,13e,15s,17z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (pgf(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring pgf have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. (12 Dec 1998) |
| prostaglandins f, synthetic | Analogs or derivatives of prostaglandins f that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pgf. (12 Dec 1998) |
| prostaglandins g | A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. most frequently encountered member of this group is the prostaglandin g2. (12 Dec 1998) |
| prostaglandins h | A group of physiologically active prostaglandin endoperoxides. They are precursors in the biosynthesis of prostaglandins and thromboxanes. The most frequently encountered member of this group is the prostaglandin h2. (12 Dec 1998) |
| prostaglandins, synthetic | Compounds obtained by chemical synthesis that are analogs or derivatives of naturally occurring prostaglandins and that have similar activity. (12 Dec 1998) |
| aromatic series | All the compounds derived from benzene, or similar cyclic compounds that obey Huckel's rule, distinguished from those compounds that are acyclic or that contain rings that lack the conjugated double bond structure characteristic of benzene. (05 Mar 2000) |
| granulocytic series | <haematology> The cells in the several stages of development in the bone marrow leading to the mature granulocyte of the circulation, e.g., myeloblasts, different stages of the myelocyte, granulocytes. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|